Stocks to Buy

Identifying winning stocks requires more than scanning headlines. InvestorPlace analysts focus on long-term themes, market timing, and structural shifts shaping where capital is flowing next, highlighting stocks positioned to benefit from those trends.

Pepsi Vs. Coke — On the Trading Floor

By Peter Cohan, InvestorPlace Writer
PepsiCo is overvalued and relatively unprofitable -- but before testing out the very profitable Coca-Cola, wait until its stock price loses some fizz.

Bristol-Myers Shares Are a Blue-Chip Keeper

By Deborah OMalley, InvestorPlace Writer
The pharmaceutical giant's stock has posted several new highs and offers an attractive dividend yield.

Build Your Materials Wealth With Kaiser Aluminum, Not Alcoa

By Peter Cohan, InvestorPlace Writer
Alcoa profit is expected to plunge, but news in the sector is not all bad. In fact, one aluminum stock looks cheap on expected 43% earnings growth.

Electronic Arts — A Risky Game Play, But Potentially Profitable

By Lawrence Meyers, InvestorPlace Contributor
Digital sales on new platforms and demand for great games present big opportunities -- and challenges -- for Electronic Arts.

Of E-Trade’s Leading Suitors, TD Ameritrade Is the Best Buy

By Will Ashworth, InvestorPlace Contributor
Toronto-Dominion's ownership, as well as a better valuation, make AMTD the smart buy -- but Schwab's poor franchise model really hits it home.

Press Your Luck on Macau Casino Stocks

By Jonathan Berr, InvestorPlace Contributor
Worries about China's economy overheating -- while legitimate -- are overblown. Buy one of these three casino stocks to capitalize on Macau's still-surging gambling scene.

Darden Restaurants Cooks Up Solid Growth

By Lawrence Meyers, InvestorPlace Contributor
Rather than pursuing rapid growth, Darden Restaurants has mastered the art of slow and steady. Here's why else it deserves a look.

Play the Mobile Revolution With Oracle

By Tom Taulli, InvestorPlace Contributor
Oracle’s growth initiatives show why it’s a mistake to write the company off as old and irrelevant.

Investment Growth? You Can Find It On eBay

By Lawrence Meyers, InvestorPlace Contributor
This online auctioneer won't ever see prices like during its dot-com heyday, but it's still a fair value that could offer price appreciation.

Is D.R. Horton a Mine in the Homebuilding Minefield?

By Lawrence Meyers, InvestorPlace Contributor
Its financial health and analyst expectations for growth five years out make D.R. Horton a bet worth considering.

Hertz’s ‘Winning’ Bid for Dollar Thrifty Is Avis’ Gain

By Will Ashworth, InvestorPlace Contributor
Avis’ decision to withdraw its offer for Dollar Thrifty leaves it better able to compete globally.

Pour Yourself a Glass of Constellation Brands

By Peter Cohan, InvestorPlace Writer
Constellation Brands is shrinking to a profitable core, supplying growth at a reasonable price. Molson Coors and Brown-Forman are a bit costly.

Family Dollar Is Worth Your Money — Costco, Target Are Bad Bargains

By Peter Cohan, InvestorPlace Writer
Target (TGT) and Costco (COST) are priced above their earnings growth, while Family Dollar (FDO) is fairly priced and well positioned to profit from economic weakness.

Costco — How to Play Wednesday’s Earnings Report

By Jamie Dlugosch, InvestorPlace Writer
A recession rarely is a tailor-made boon for most companies, but Costco's bargain prices have lured in penny-pinching customers. Here's what to expect.

Line Your Portfolio With Crocs, Wolverine

By Peter Cohan, InvestorPlace Writer
Crocs’ rapid growth, wide margins and low valuation make it a compelling buy; Wolverine has upside potential, too.

Don’t Bet Your Chips on Intel, Micron

By Peter Cohan, InvestorPlace Writer
Don't bet your chips on these two stocks. One is solid but growing too slowly, and the other is too hard to predict.

4 Stocks for an Unexpected Recovery

By Daniel Putnam, InvestorPlace Contributor
Given the market’s tendency to catch the “crowd” off-guard, it’s time to start putting together a list of stocks that can outperform if things unexpectedly turn around. Here's a start.

9 Healthy Biotech Buys

By Louis Navellier, Editor, Growth Investor
Baby boomers are getting older and in need of more and more treatments, thus the race for the next big blockbuster drug. Smaller biotechs are cashing in.

Cognizant, Accenture a Pair of Outsourcing Dynamos

By Peter Cohan, InvestorPlace Writer
This pair of global outsourcers give you growth at a reasonable price -- but avoid Computer Sciences Corp. and watch out for growth slowdown.
Load More Articles